Laddar...
Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
BACKGROUND: PCSK9 inhibition is a new powerful cholesterol-lowering strategy. Recently, it was reported that CETP inhibitors influence PCSK9 levels as an off-target effect. We explored the relationship between circulating PCSK9 levels and CETP activity in patients with metabolic disease who were not...
Sparad:
| I publikationen: | Cardiovasc Diabetol |
|---|---|
| Huvudupphovsmän: | , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BioMed Central
2016
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4973048/ https://ncbi.nlm.nih.gov/pubmed/27488210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-016-0428-z |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|